Ataxia-Telangiectasia: Prognosis, Life Expectancy, and Management

Understanding Ataxia-Telangiectasia (A-T)

A-T is a rare, autosomal recessive neurodegenerative disorder caused by ATM gene mutations. It affects the nervous system, immune system, and increases cancer risk.

Prognosis and Life Expectancy

• Average life expectancy: ~20 years (range: early childhood to 40s).
• Variable severity: Some have milder neurological involvement and longer survival.

Key Prognostic Factors

Factor	Impact
Neurological severity	Milder ataxia → better outlook
Respiratory complications	Bronchiectasis, recurrent pneumonia → leading cause of death
Cancer risk	Leukemia, lymphoma; risk rises with age
Other organ involvement	Heart, liver disease can shorten survival

Multidisciplinary Management

• Physical/occupational therapy: Maintain mobility, prevent falls, adapt daily activities.
• Speech therapy: Address dysarthria, swallowing difficulties.
• Respiratory care: Airway clearance, prompt antibiotic treatment, vaccinations (pneumococcal, influenza).
• Immunoglobulin replacement: For humoral immune deficiency.
• Cancer surveillance: Regular CBC, lymph node exams, imaging per protocol.
• Genetic counseling: For family planning and carrier testing.

While no cure exists, comprehensive care improves quality of life and extends survival. Early diagnosis and proactive management are crucial.